Published in Blood on December 01, 1998
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | NCT04197219
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res (2005) 4.08
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 2.94
Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer (2009) 2.23
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) (2015) 2.17
A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med (2010) 2.06
Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood (2011) 2.05
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70
Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol (2010) 1.67
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol (2016) 1.49
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood (2011) 1.47
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood (2007) 1.38
The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer (2005) 1.35
Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev (2006) 1.32
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer (2008) 1.30
Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci (2013) 1.26
Control of the immune response by pro-angiogenic factors. Front Oncol (2014) 1.26
Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest (2006) 1.26
Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood (2006) 1.25
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer (2009) 1.25
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res (2012) 1.23
The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol (2014) 1.22
Memory T cells need CD28 costimulation to remember. Semin Immunol (2009) 1.22
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood (2005) 1.21
Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol (2012) 1.18
Lymphangiogenesis and cancer. Genes Cancer (2011) 1.16
Tumours can act as adjuvants for humoral immunity. Immunology (2001) 1.14
Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells (2014) 1.14
PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling. Mol Cell Biol (2010) 1.14
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma (2008) 1.11
SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer (2003) 1.11
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J (2009) 1.06
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood (2008) 1.06
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov (2016) 1.06
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol (2012) 1.05
Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem (2009) 1.05
Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol (2013) 1.05
Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα. Eur J Immunol (2012) 1.04
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep (2015) 1.03
A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia (2005) 1.02
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol (2007) 1.02
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res (2010) 1.01
Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol (2012) 1.01
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 0.99
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med (2017) 0.98
The roles of mast cells in anticancer immunity. Cancer Immunol Immunother (2012) 0.98
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med (2005) 0.97
Dendritic cell density and activation status in human breast cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer (2002) 0.97
Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol (2012) 0.97
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A (2007) 0.96
Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther (2013) 0.96
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy (2016) 0.96
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer (2011) 0.94
Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun (2005) 0.93
Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res (2012) 0.93
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol (2015) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood (2013) 0.92
Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J Immunol (2009) 0.92
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology (2012) 0.91
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91
Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc Natl Acad Sci U S A (2016) 0.90
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res (2014) 0.90
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Reciprocal regulation between TOC1 and LHY/CCA1 within the Arabidopsis circadian clock. Science (2001) 6.63
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Cloning of the Arabidopsis clock gene TOC1, an autoregulatory response regulator homolog. Science (2000) 5.91
Genes involved in organ separation in Arabidopsis: an analysis of the cup-shaped cotyledon mutant. Plant Cell (1997) 5.21
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
Molecular interaction between COP1 and HY5 defines a regulatory switch for light control of Arabidopsis development. Mol Cell (1998) 4.10
Man's place in Hominoidea revealed by mitochondrial DNA genealogy. J Mol Evol (1992) 3.53
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
The CUP-SHAPED COTYLEDON1 gene of Arabidopsis regulates shoot apical meristem formation. Development (2001) 3.05
Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut (2008) 2.75
Shoot apical meristem and cotyledon formation during Arabidopsis embryogenesis: interaction among the CUP-SHAPED COTYLEDON and SHOOT MERISTEMLESS genes. Development (1999) 2.68
HY5 stability and activity in arabidopsis is regulated by phosphorylation in its COP1 binding domain. EMBO J (2000) 2.67
Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst (1993) 2.66
Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol (1998) 2.62
Human mtDNA and Y-chromosome variation is correlated with matrilocal versus patrilocal residence. Nat Genet (2001) 2.57
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res (1999) 2.49
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer (2005) 2.37
Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest (1998) 2.36
E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci U S A (1994) 2.35
Regulation of mast cell survival by IgE. Immunity (2001) 2.11
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem (1981) 2.05
Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidinic lyase, a functional mutM homologue. Cancer Res (1997) 2.02
Feline immunodeficiency virus infection. Vet Immunol Immunopathol (1989) 2.00
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol (1998) 1.97
High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) (2004) 1.95
Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res (2000) 1.95
Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res (1997) 1.95
Reconstruction of genomic rearrangements in great apes and gibbons by chromosome painting. Proc Natl Acad Sci U S A (1992) 1.88
Mitochondrial DNA polymorphism among five Asian populations. Am J Hum Genet (1988) 1.86
Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells. J Exp Med (1991) 1.82
Structural and functional studies of MinD ATPase: implications for the molecular recognition of the bacterial cell division apparatus. EMBO J (2001) 1.81
Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst (1993) 1.73
EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer (2008) 1.73
Granular cell ameloblastoma. A rare variant. Int J Oral Maxillofac Surg (1989) 1.71
Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol (2010) 1.67
Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res (2001) 1.65
A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet (1996) 1.65
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia (2010) 1.64
Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem (1997) 1.60
Nosocomial contamination by Mycobacterium gordonae in hospital water supply and super-oxidized water. J Hosp Infect (2002) 1.56
VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res (2001) 1.55
Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med (1994) 1.53
Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng (2001) 1.52
Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol (1995) 1.49
The diagnosis of mild emphysema. Correlation of computed tomography and pathology scores. Am Rev Respir Dis (1990) 1.49
Preparation and physicochemical properties of green pea superoxide dismutase. Biochim Biophys Acta (1972) 1.48
In situ hybridization with biotinylated tyramide amplification: detection of human papillomavirus DNA in cervical neoplastic lesions. Mod Pathol (1998) 1.48
Orally active antioxidative copper(II) aspirinate: synthesis, structure characterization, superoxide scavenging activity, and in vitro and in vivo antioxidative evaluations. J Biol Inorg Chem (2005) 1.47
Hazards of steroids in association with anaesthesia. Can Anaesth Soc J (1969) 1.47
Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. Chest (2001) 1.46
Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut (2007) 1.46
Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer (2004) 1.43
Recurrence of breast cancer following local excision alone for ductal carcinoma in situ. Breast Cancer (2001) 1.41
c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun (1995) 1.40
A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of notch and a CSL protein to build a transcriptional activator complex on target promoters. Mol Cell Biol (2001) 1.40
Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol (1996) 1.39
Discitis, infectious arthritis, and bacterial meningitis in a patient with pancreatic diabetes. Intern Med (1997) 1.39
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun (1978) 1.38
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol (2000) 1.38
Identification, by activated carbon injection, of cancer lesion during laparoscopic surgery. Lancet (1994) 1.38
KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis (1993) 1.38
Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol (1998) 1.36
c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun (1994) 1.34
Results of 271 funnel chest operations. Ann Thorac Surg (1970) 1.34
Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Hum Pathol (2001) 1.34
Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells. J Biol Chem (2001) 1.33
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res (1990) 1.33
Mechanotransduction in endothelial cells: temporal signaling events in response to shear stress. J Vasc Res (1997) 1.32
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer (2006) 1.29
Inflammatory responses to ischemia and reperfusion in skeletal muscle. Mol Cell Biochem (1998) 1.28
Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation (2000) 1.27
Malignant mixed epithelial and stromal tumours of the kidney: a report of the first two cases with a fatal clinical outcome. Histopathology (2004) 1.26
MR detection of degenerating uterine leiomyomas. J Comput Assist Tomogr (1993) 1.25
Computerized analysis of the likelihood of malignancy in solitary pulmonary nodules with use of artificial neural networks. Radiology (2000) 1.25
Mucosectomy in the colon with endoscopic submucosal dissection. Endoscopy (2005) 1.24
Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. Circ Res (1998) 1.24
Analysis of the mRNA cap-binding ability of human eukaryotic initiation factor-4E by use of recombinant wild-type and mutant forms. Eur J Biochem (1996) 1.23
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer (2012) 1.23
A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res (1993) 1.22
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene (2009) 1.22
A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol (1999) 1.22
Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) (2005) 1.22
Refined x-ray structure of papain.E-64-c complex at 2.1-A resolution. J Biol Chem (1991) 1.21
Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer (2005) 1.21